The Senate invoked cloture Wednesday afternoon with a vote of 53–47, a party-line split. In response, Democrats decided not ...

One of Robert F. Kennedy Jr.’s most devoted cheerleaders, Dr. Patrick Soon-Shiong, the billionaire owner of the Los Angeles ...

California-based ImmunityBio has entered into a collaboration and supply agreement with Sino-American biotech BeiGene (to be ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zoetis (ZTS – Research Report), Terns ...

ImmunityBio will part with 10 employees this quarter. Last fall, it cut 31 employees. The moves come as the biotech works to ...

We recently compiled a list of the 10 Firms Lead Thursday’s Rally on Better Earnings, Bargain-Hunting. In this article, we ...

HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

In this article, we will take a look at the 12 stocks that will double in 2025.

The trial is anticipated to enrol 462 subjects and aims to confirm the safety and efficacy of the combination.

Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).